Venus Remedies Limited

NSE VENUSREM.NS

Venus Remedies Limited Price to Sales Ratio (P/S) on February 06, 2025: 0.75

Venus Remedies Limited Price to Sales Ratio (P/S) is 0.75 on February 06, 2025, a -18.43% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Venus Remedies Limited 52-week high Price to Sales Ratio (P/S) is 0.97 on February 14, 2024, which is 28.15% above the current Price to Sales Ratio (P/S).
Venus Remedies Limited 52-week low Price to Sales Ratio (P/S) is 0.60 on January 28, 2025, which is -20.70% below the current Price to Sales Ratio (P/S).
Venus Remedies Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 0.76.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NSE: VENUSREM.NS

Venus Remedies Limited

CEO	Mr. Ashutosh Jain B.A., LL.B
IPO Date	Dec. 20, 2006
Location	India
Headquarters	Plot 51-52, Industrial Area
Employees	1,187
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Key trends

Past 5 years